Paclitaxel-albumin is named as a drug or biological intervention in 6 clinical trials in our China trial register, 5 of which are recruiting. Lead sponsors include Tongji Hospital (2), Sun Yat-sen University (1) and Beijing Tongren Hospital (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Cervical Cancer; Neoadjuvant Chemoimmunotherapy; Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Cervical Cancer | 2 |
| Neoadjuvant Chemoimmunotherapy | 2 |
| Breast Cancer | 1 |
| Neoadjuvant Chemotherapy | 1 |
| Radical Hysterectomy | 1 |
| Extrafascial Hysterectomy | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Esophageal Cancer | 1 |
| Fludzoparib" and Anti-angiogenic | 1 |
| HRD-positive/HER2-negative Advanced Breast Cancer | 1 |
| Locally Advanced Cervical Cancer | 1 |
| PD-L1 Negative | 1 |
| Lead sponsor | Trials |
|---|---|
| Tongji Hospital | 2 |
| Sun Yat-sen University | 1 |
| Beijing Tongren Hospital | 1 |
| The First Affiliated Hospital of Zhengzhou University | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Register | Paclitaxel-albumin trials |
|---|---|
| Clinical trials in China | 6 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Paclitaxel-albumin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Paclitaxel-albumin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.